(January 12, 2021, 1:52 PM EST) -- ALEXANDRIA, Va. — The maker of an antibody cocktail that recently won emergency use authorization for the treatment of COVID-19 is being challenged on a different front before the Patent Trial and Appeal Board, with a Jan. 11 petition for post-grant review (PGR) that takes aim at a patented vascular endothelial growth factor (VEGF) antagonist for sufferers of age-related macular degeneration (AMD)....